Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions
Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis
Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC